#United States #IDEAYA Biosciences #South San Francisco #Precision Medicine #Investor R&D Day

IDEAYA Biosciences to Host Investor R&D Day in London

IDEAYA Biosciences, a prominent company in the field of precision medicine focused on oncology, is gearing up for its Investor R&D Day scheduled for November 16, 2026, in London. This event marks a significant opportunity for investors and stakeholders to gain insights into the company's innovative strategies and upcoming projects.

Event Highlights

On this day, IDEAYA management will delve into their groundbreaking research surrounding the MTAP/CDKN2A and KRAS development strategy as it pertains to pancreatic cancer. The agenda includes a thorough discussion about new preclinical data and rational combination strategies aimed at tackling tumor heterogeneity and adaptive plasticity. One of the highlights of the event will be a special presentation by Dr. Frank McCormick of the UCSF Helen Diller Family Comprehensive Cancer Center, who will share insights into the latest advancements in cancer treatments.

Registration Details

For those interested in attending, in-person attendance as well as virtual participation is available, and advance registration is mandatory. Interested individuals can find more information and register through the link to the official event page: Register Here.

Upcoming Investor Conferences

In addition to the R&D Day in London, IDEAYA will participate in several notable investor conferences in September 2026:

• - Wells Fargo 21st Annual Healthcare Conference: September 8, 2026, 3:00 PM ET in Boston, Massachusetts. This session will feature a fireside chat with CEO Yujiro S. Hata and CFO Joshua Bleharski.
• - Cantor Global Healthcare Conference: September 9, 2026, 11:30 AM ET in New York. This event is another chance to hear from CEO Yujiro Hata.
• - Citi's 2026 Biopharma Back to School Conference: September 10, 2026, 2:40 PM ET in New York, focusing on new updates in biopharmaceuticals.
• - Morgan Stanley 24th Annual Global Healthcare Conference: September 14, 2026, at 7:00 AM ET in New York, where Mr. Hata will again address investors.

Each of these conferences will also host live audio webcasts, accessible through the IDEAYA website. Recordings will be available for 30 days following the live events, ensuring that interested parties can catch up on the discussions.

About IDEAYA Biosciences

IDEAYA is at the forefront of precision oncology, committed to revolutionizing cancer treatment through personalized therapies. The company's approach combines expertise in drug discovery, structural biology, and bioinformatics, with a strong emphasis on validating biomarkers for developing tailor-made treatments that target the specific genetic drivers of various cancers.

With a robust pipeline focusing on synthetic lethality and antibody-drug conjugates (ADCs), IDEAYA aims to introduce transformative therapies that not only improve clinical outcomes but also significantly alter the landscape of cancer treatment. The firm’s mission is clear: to provide targeted therapies designed to be more effective and personalized, ultimately enhancing patient care in oncology.

This upcoming R&D Day, alongside participation in prominent investor events, demonstrates IDEAYA's commitment to transparency and engagement with its investor community, as it continues to pave the way in the precision oncology space.

For further updates, stakeholders can refer to the official IDEAYA Biosciences website and their ongoing publications.